Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D HellmannLuis Paz-AresReyes Bernabe CaroBogdan ZurawskiSang-We KimEnric Carcereny CostaKeunchil ParkAurelia AlexandruLorena LupinacciEmmanuel de la Mora JimenezHiroshi SakaiIstvan AlbertAlain VergnenegreSolange PetersKonstantinos SyrigosFabrice BarlesiMartin ReckHossein BorghaeiJulie R BrahmerKenneth J O'ByrneWilliam J GeesePrabhu BhagavatheeswaranSridhar K RabindranRavi S KasinathanFaith E NathanSuresh S RamalingamPublished in: The New England journal of medicine (2019)
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).